DAX-0,68 % EUR/USD+0,20 % Gold+0,02 % Öl (Brent)-0,17 %

VALEANT PHARMA - Allergan-Übernahme beflügelt (Seite 90)

Begriffe und/oder Benutzer


Für die Shorties ist doch hier nur mehr wenig Fleisch an der Aktie.
Verstehe das sie massiv bei Kursen über 100 USD oder bei sogar über 200 USD short gingen.
Aber der größte Teil des Profites ist doch bereits eingefahren, oder?
Auf die letzten 10 USD wird es nicht mehr ankommen...
Antwort auf Beitrag Nr.: 54.583.083 von Promethium am 21.03.17 19:47:08naja...wenn da wetten auf 0$ je Aktie gibt,dann machen die das noch...heute sind wieder große Pakete über den Tisch geschmißen
das Problem momentan, die Angst vor Valeant-aktie steckt richtig in Knochen ,deswegen fehlen die Nachkäufer
also der sprung heute kam wegen die Nachricht von heute mit Abschluß aller Refinanzierungen ...so dass nach erlös der Fälligkeiten mit dem gesammelten Geld insgesamt (6,2Milliard) + Kassenbestand werden alle Schulden für die Jahre 2018,2019,2020 zurückbezahl.... Papa wird die shories bald zeigen wo der Hammer hängt...

Valeant Completes Refinancing Transactions
LAVAL, Quebec, March 21, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has closed its previously announced refinancing transactions. These transactions include its offering of $1.25 billion aggregate principal amount of 6.50% senior secured notes due 2022 and $2.0 billion aggregate principal amount of 7.00% senior secured notes due 2024, and its borrowing of an additional approximately $3 billion of new term loans maturing in 2022. The Company used the proceeds of the offering and the new term loan together with cash on hand to repay all term loans under its credit facility maturing in 2018, 2019 and 2020, $350 million of revolver borrowings and $1.1 billion of its 6.75% Senior Notes due 2018.

In addition, as part of these transactions, the Company amended its existing credit agreement to remove the financial maintenance covenants from the term loans and modify the financial maintenance covenants under the revolving facility and to make certain other amendments.

"Upon closing these transactions, the issuance of $1.25 billion and $2.0 billion of senior secured notes due 2022 and 2024, respectively, and the tender for $1.1 billion of our Senior Notes due 2018, the amount of our debt maturing prior to 2020 will be substantially reduced," said Joseph C. Papa, Chairman and CEO of Valeant. "In addition, the amended terms of the credit agreement will provide us with improved operating flexibility and a greater margin of safety with respect to financial covenants. Together, these transactions, coupled with our ongoing asset sale process, will enable Valeant to focus on driving the fundamental operating performance of its various businesses. We want to thank the lenders, investors and other financial institutions that supported us in the completion of this important initiative."

See the Annex to this press release for further details about the refinancing and its impact on our capital structure.
Antwort auf Beitrag Nr.: 54.556.960 von marty44 am 17.03.17 15:35:05

Bausch + Lomb Canada Launches BEPREVE®
Latest Eye Health Innovation Indicated for Seasonal and Chronic Eye Allergies to "Stop the Itch"

LAVAL, QC, March 22, 2017 /CNW/ - Bausch + Lomb, a leading global eye health company, today announced through its Canadian affiliate the availability in Canada of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%w/v, an innovative fast acting eye drop indicated for the treatment of itch associated with allergic conjunctivitis.

Allergic conjunctivitis is inflammation of the eye caused by an allergic reaction to allergens such as pollen, house dust, or animal dander. Affecting as many as 30% of the population, allergic conjunctivitis is increasing in incidence.1

"In my practice, I see many patients who suffer from allergic conjunctivitis and experience discomfort from itchy eyes," said Randall Thomas, M.D., an ophthalmologist from Concord, North Carolina. "BEPREVE® has been a welcome medicine that has allowed me to effectively help patients with itchy eyes due to seasonal and chronic allergies."

BEPREVE® is the first innovative product for allergic conjunctivitis to be introduced to the Canadian market in six years. It is a dual acting antihistamine that works by blocking the effects of histamine - a chemical that plays an important role in allergic reactions, and stabilizing mast cells - cells that contain chemicals involved in allergic reactions. In clinical trials, BEPREVE® demonstrated a 73.4% reduction in itchy eyes in as rapidly as three minutes.2

"Bausch + Lomb Canada is proud to offer patients an innovative product that reduces the intensity of allergic reactions and associated eye itchiness, allowing them to focus on what is important in their lives," says Lorenzo Santini, general manager, Bausch + Lomb Canada. "BEPREVE® will complement Bausch + Lomb's existing prescription ophthalmology family of products, including ALREX®, LOTEMAX® Gel, PROLENSA®, and branded OTC eye vitamins, PreserVision® and Ocuvite®."

eindeutig wieder mal Leerverkäufe...immer bei positiven Nachrichten reagieren die Shroti mit Leerverkäufe darauf....
ich habe mir den Chartverlauf seit Sep. 2016 angeschaut...Aktie von über 30$ auf jetztiger Kurs..was ist passiert.. Schilden waren im Sept. auch schon bekannt.... Aussichten und Prognose war auch so erwartet....

im Gegenteil sind 1 Monat viel positive Meldungen gekommen und neue Zulassungen, Refinanzierung, Schuldenabbau, Schuldenfälligkeit verschoben...

das wird sich irgendwann in den Kurs niederschlagen müssen und werden und ist die Rache richtig süß

On behalf of the Board of Directors of Valeant Pharmaceuticals International, Inc. (the “Company”), I want to take this opportunity to invite you to attend our 2017 Annual Meeting of Shareholders. The meeting will be held at 9:00 a.m., local time, on Tuesday, May 2, 2017 at the Company’s offices located at 2150 Saint Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8. At the meeting, shareholders will vote on the proposals set forth in the Notice of Annual Meeting and the accompanying management proxy circular and proxy statement (the “Proxy Statement”), as well as receive a report on the progress of the Company.

Beitrag zu dieser Diskussion schreiben